ABSTRACT
Fulminant hepatic failure (FHF) continues to be one of the most devastating conditions affecting thousands o f individuals each year. By definition, these are patients who were previously healthy without any known underlying liver disease. Historically, the outcome of these patients in most cases has been poor. With the introduction o f orthotopic liver transplantation in the late seventies and following the NIH consensus conference on liver transplantation in 1983, orthotopic liver transplantation became an accepted thera peutic modality for patients with end stage liver disease and was no longer considered an experimental procedure. Since then, liver transplantation has been used as a treatment modality for patients with FHF, with a significant increase in patient survival and reduction in the associated morbidity.
